Cargando…

The study of COVID-19 infection following vaccination in patients with multiple sclerosis

BACKGROUND: At this time vaccination against SARS-CoV2 is a global priority. Cases with multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated the change in the frequency of COVID-19 after vaccination and the associated factors with severe COVID-19 infection before...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadiri, Fereshteh, Sahraian, Mohammad Ali, Azimi, Amirreza, Moghadasi, Abdorreza Naser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559439/
https://www.ncbi.nlm.nih.gov/pubmed/35158433
http://dx.doi.org/10.1016/j.msard.2021.103363
_version_ 1784592760180834304
author Ghadiri, Fereshteh
Sahraian, Mohammad Ali
Azimi, Amirreza
Moghadasi, Abdorreza Naser
author_facet Ghadiri, Fereshteh
Sahraian, Mohammad Ali
Azimi, Amirreza
Moghadasi, Abdorreza Naser
author_sort Ghadiri, Fereshteh
collection PubMed
description BACKGROUND: At this time vaccination against SARS-CoV2 is a global priority. Cases with multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated the change in the frequency of COVID-19 after vaccination and the associated factors with severe COVID-19 infection before and after full vaccination. METHODS: A questionnaire was validated to investigate the basic characteristics (age, gender, education, body mass index, smoking status, and comorbidities), MS disease and treatment status (MS type, MS duration, The Expanded Disability Status Scale (EDSS), disease modifying treatments) and the information about COVID-19 infection and severity. RESULTS: 692 (91.9%) of participants have received both doses of vaccines, of which Sinopharm appeared to be the most common type. Significant difference of COVID-19 infection prevalence was seen before vaccination and after full vaccination (difference: 0.16, 95% CI: 0.12–0.20) (p value < 0.001). The difference was not significant for severe cases (those who were admitted in the ward or ICU) relative to the COVID-19 cases or the whole participants. Of all the basic and disease factors, only EDSS showed a significant association with severe COVID-19 before vaccination. Severe COVID-19 in fully vaccinated cases did not show any significant relation to any of basic or disease characteristics except with prior history of severe allergic reactions (OR: 17.1, p value: 0.001). DISCUSSION: The decreased frequency of infection with SARS-CoV2 was predictable but the insignificant difference in cases with the severe forms of the disease raise concern. The only significant predictor was found to be severe allergic reactions. As there are debates on antiCD20 s association with severe COVID-19 and vaccine efficacy, we could not find such significant relation. The other noticeable point about the found relation of EDSS and critical COVID-19 before vaccination is the absence of such relation after full vaccination.
format Online
Article
Text
id pubmed-8559439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-85594392021-11-01 The study of COVID-19 infection following vaccination in patients with multiple sclerosis Ghadiri, Fereshteh Sahraian, Mohammad Ali Azimi, Amirreza Moghadasi, Abdorreza Naser Mult Scler Relat Disord Article BACKGROUND: At this time vaccination against SARS-CoV2 is a global priority. Cases with multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated the change in the frequency of COVID-19 after vaccination and the associated factors with severe COVID-19 infection before and after full vaccination. METHODS: A questionnaire was validated to investigate the basic characteristics (age, gender, education, body mass index, smoking status, and comorbidities), MS disease and treatment status (MS type, MS duration, The Expanded Disability Status Scale (EDSS), disease modifying treatments) and the information about COVID-19 infection and severity. RESULTS: 692 (91.9%) of participants have received both doses of vaccines, of which Sinopharm appeared to be the most common type. Significant difference of COVID-19 infection prevalence was seen before vaccination and after full vaccination (difference: 0.16, 95% CI: 0.12–0.20) (p value < 0.001). The difference was not significant for severe cases (those who were admitted in the ward or ICU) relative to the COVID-19 cases or the whole participants. Of all the basic and disease factors, only EDSS showed a significant association with severe COVID-19 before vaccination. Severe COVID-19 in fully vaccinated cases did not show any significant relation to any of basic or disease characteristics except with prior history of severe allergic reactions (OR: 17.1, p value: 0.001). DISCUSSION: The decreased frequency of infection with SARS-CoV2 was predictable but the insignificant difference in cases with the severe forms of the disease raise concern. The only significant predictor was found to be severe allergic reactions. As there are debates on antiCD20 s association with severe COVID-19 and vaccine efficacy, we could not find such significant relation. The other noticeable point about the found relation of EDSS and critical COVID-19 before vaccination is the absence of such relation after full vaccination. Elsevier B.V. 2022-01 2021-11-01 /pmc/articles/PMC8559439/ /pubmed/35158433 http://dx.doi.org/10.1016/j.msard.2021.103363 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ghadiri, Fereshteh
Sahraian, Mohammad Ali
Azimi, Amirreza
Moghadasi, Abdorreza Naser
The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title_full The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title_fullStr The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title_full_unstemmed The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title_short The study of COVID-19 infection following vaccination in patients with multiple sclerosis
title_sort study of covid-19 infection following vaccination in patients with multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559439/
https://www.ncbi.nlm.nih.gov/pubmed/35158433
http://dx.doi.org/10.1016/j.msard.2021.103363
work_keys_str_mv AT ghadirifereshteh thestudyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT sahraianmohammadali thestudyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT azimiamirreza thestudyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT moghadasiabdorrezanaser thestudyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT ghadirifereshteh studyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT sahraianmohammadali studyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT azimiamirreza studyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis
AT moghadasiabdorrezanaser studyofcovid19infectionfollowingvaccinationinpatientswithmultiplesclerosis